TD Securities Sees Strong 2026 Growth for Tempus AI
TD Cowen upgraded Tempus AI to Buy, $65 target, citing strong growth in AI pharma tools despite recent stock drop.
/ 9 items
#TEM↓
Tempus AI Gets a $100 Price Target – Why Mizuho Sees Big Upside in Precision Oncology
Mizuho starts coverage on Tempus AI with Outperform rating and $100 price target. Leader in AI-powered precision oncology in a $40B market growing 30% annually—growth undervalued today.
Nancy Pelosi's Latest Stock Moves: Big Bets on Tech Giants
Nancy Pelosi disclosed major stock transactions in January 2026, including exercising options on Amazon, Google, and Nvidia while selling Apple shares worth millions.
Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
Tempus AI Hits Major Profit Goal Amidst Rapid Q3 2025 Growth
Tempus AI achieved its 10-year profitability target in Q3 2025, driven by massive 84.7% revenue growth and exceptional performance in its genomics and clinical testing divisions.
Canaccord Launches Tempus AI Coverage with $110 Price Target
Canaccord initiates Tempus AI with Buy rating and $110 target, citing strong growth potential from AI-powered oncology testing and genomic profiling services.